Primary objective: To provide reliable estimates of the effect of study treatments on all-cause mortality at 28 days after first randomisation.
Type of study: Interventional; Phase III, treatment
Treatment tested: Lopinavir/Ritonavir, low dose corticosteroids, Hydroxychloroquine, Azithromycin, Convalescent plasma and Tocilizumab
Sample size: 12,000
Study participants: Hospitalized, SARS-CoV-2 Infection (clinically suspected or laboratory confirmed) with no medical history that might in the opinion of the attending clinician, put the patient at significant risk if she/he were to participate to the trial
Study status: Recruiting
- Peter W Horby: firstname.lastname@example.org
Last updated: June 2020
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.